ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Environment

Obviousness ruling

July 2, 2007 | APPEARED IN VOLUME 85, ISSUE 27

THE SUPREME COURT'S ruling is rather ridiculous (C&EN, May 7, page 13). Because of the complexity of some racemates, resolving them into the component stereoisomers is no easy task. Any company that succeeds in this process deserves a patent, not just a process patent but a patent on the active isomer. This presumes that the other isomer will not be found "effective" for some other use and approved by the Food & Drug Administration, actually doing more harm than good.

Art Goldkamp
Redmond, Wash.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment